Psychodynamic Therapy: Modern Evidence Base, Short-Term vs Long-Term Formats, and Head-to-Head Comparison with CBT

Psychodynamic therapy (PDT) is among the oldest continuously practiced psychotherapies, with theoretical roots in psychoanalytic theory and a clinical lineage extending over a century. Despite its historical prominence, PDT has faced persistent criticism regarding its evidence base — a critique that has substantively shifted over the past two decades as a growing body of randomized controlled trials (RCTs), meta-analyses, and neuroimaging research has accumulated. Today, PDT occupies a complex but increasingly well-defined position in the evidence-based treatment landscape.

Modern psychodynamic therapy encompasses a broad family of interventions unified by core technical and theoretical commitments: attention to unconscious processes, the therapeutic relationship as a vehicle for change, the role of early attachment experiences in shaping adult relational patterns, and the importance of affect and defense analysis. These interventions are typically divided into short-term psychodynamic psychotherapy (STPP), typically 16–30 sessions, and long-term psychodynamic psychotherapy (LTPP), generally exceeding 50 sessions or lasting one year or more. This distinction is clinically and empirically significant, as the two formats have different evidence profiles, different indications, and likely different mechanisms of action.

This article provides a clinician-level review of PDT's modern evidence base, including neurobiological mechanisms, specific outcome data with effect sizes and response rates, head-to-head comparisons with cognitive-behavioral therapy (CBT), prognostic factors, and current research frontiers. The goal is to move beyond the polarized "psychodynamic vs. CBT" debate and toward a nuanced understanding of when, for whom, and how psychodynamic interventions produce clinical change.

Contemporary psychodynamic therapy draws on several overlapping theoretical traditions — ego psychology, object relations theory, self psychology, attachment theory, and relational psychoanalysis — but shares a set of core technical features that distinguish it from other modalities. Jonathan Shedler's influential 2010 paper in American Psychologist identified seven defining features of psychodynamic technique:

• Focus on affect and expression of emotion: Helping patients identify, experience, and articulate emotional states, including those outside awareness.
• Exploration of attempts to avoid distressing thoughts and feelings: Analysis of psychological defenses and resistance.
• Identification of recurring themes and patterns: Recognizing repetitive relational and behavioral patterns across contexts and across time.
• Discussion of past experience: Particularly developmental experiences and early attachment relationships that shaped current functioning.
• Focus on interpersonal relations: Current relationships as both a source of distress and a target of intervention.
• Focus on the therapeutic relationship: Using transference and the real relationship as a window into the patient's relational world.
• Exploration of fantasy life: Dreams, fantasies, wishes, and fears as clinically meaningful material.

In short-term formats, these techniques are typically organized around a core conflictual relationship theme (CCRT) or a focal dynamic formulation. Manualized STPP models include Luborsky's Supportive-Expressive Therapy, Strupp's Time-Limited Dynamic Psychotherapy, Davanloo's Intensive Short-Term Dynamic Psychotherapy (ISTDP), and Abbass's adaptation of ISTDP. In long-term formats, the work is less focal and permits deeper exploration of characterological patterns, personality organization, and unconscious conflict.

Critically, modern PDT is not synonymous with classical psychoanalysis. The stereotyped image of the silent analyst and the couch is largely historical. Contemporary psychodynamic clinicians are typically active, relationally engaged, and informed by attachment research and affective neuroscience. This evolution is important for contextualizing the evidence base, as the PDT studied in modern RCTs is substantially different from the psychoanalysis of the mid-20th century.

A growing body of neuroimaging research has begun to elucidate the neural mechanisms through which psychodynamic therapy produces clinical change. While this literature is smaller than the corresponding CBT neuroimaging literature, it reveals both overlapping and distinct patterns of brain change.

Prefrontal-Limbic Circuitry and Emotion Regulation

The prevailing neurobiological model of psychotherapy-induced change centers on the prefrontal-limbic circuit — specifically, the relationship between the medial prefrontal cortex (mPFC), the dorsolateral prefrontal cortex (dlPFC), the anterior cingulate cortex (ACC), and the amygdala. In anxiety and depressive disorders, this circuit typically shows amygdala hyperactivation and prefrontal hypoactivation, reflecting impaired top-down regulation of emotional responses.

Neuroimaging studies of PDT suggest that successful treatment is associated with increased prefrontal activation during emotional processing tasks and decreased amygdala reactivity to threatening or emotionally salient stimuli. A landmark 2013 fMRI study by Buchheim and colleagues published in PLoS ONE examined patients with major depressive disorder before and after 15 months of psychoanalytic therapy. They found significant reductions in amygdala and subgenual cingulate activation during personalized attachment narratives, with changes correlating with symptomatic improvement. This is notable because the subgenual anterior cingulate cortex (sgACC, Brodmann area 25) is a key node in the neurocircuitry of depression — the same region targeted by deep brain stimulation in treatment-resistant depression.

Default Mode Network and Self-Referential Processing

Psychodynamic therapy's emphasis on self-reflection, narrative coherence, and insight aligns with the function of the default mode network (DMN), which includes the medial prefrontal cortex, posterior cingulate cortex, precuneus, and angular gyrus. The DMN is activated during self-referential processing, autobiographical memory retrieval, and mentalizing — all core activities in psychodynamic treatment. Emerging research suggests that PDT may modulate DMN connectivity in ways that promote more flexible and integrated self-representation, although this remains an active area of investigation.

Oxytocin, Attachment, and the Therapeutic Relationship

The therapeutic alliance — considered the primary vehicle of change in PDT — has neurobiological correlates in the oxytocinergic system. Oxytocin, a neuropeptide involved in social bonding, trust, and attachment, is released during positive social interactions and has been shown to reduce amygdala reactivity. While direct measurement of oxytocin changes during PDT is limited, the theoretical framework is well-supported: a secure therapeutic relationship may function as a corrective attachment experience that engages the oxytocin system, facilitating emotional processing and fear extinction.

Neurotransmitter Systems

PDT's effects on specific neurotransmitter systems are less well-characterized than those of pharmacotherapy, but several lines of evidence are relevant. Successful psychotherapy for depression — including PDT — has been associated with normalization of serotonergic function, as indexed by changes in serotonin transporter binding measured via PET. Additionally, the hypothalamic-pituitary-adrenal (HPA) axis, which is dysregulated in depression and PTSD (with cortisol hypersecretion in depression and blunted cortisol in some PTSD subtypes), shows normalization following psychodynamic treatment. A study by Huber and colleagues (2012) found that long-term psychoanalytic therapy produced greater normalization of cortisol awakening responses compared to CBT in depressed patients at three-year follow-up, suggesting deeper modulation of stress-response systems.

Neuroplasticity and Epigenetic Mechanisms

At the molecular level, psychotherapy is hypothesized to produce lasting change through neuroplastic mechanisms including synaptogenesis, long-term potentiation, and epigenetic modification. Brain-derived neurotrophic factor (BDNF), a key mediator of neuroplasticity, is reduced in depression and increases with successful treatment. While most BDNF research in psychotherapy has involved CBT, the mechanism is presumably transdiagnostic and transtherapeutic. Emerging research on epigenetic modifications — particularly methylation changes in stress-response genes such as NR3C1 (the glucocorticoid receptor gene) and FKBP5 — suggests that psychotherapy may produce lasting changes in gene expression that mediate long-term vulnerability reduction.

Short-term psychodynamic psychotherapy, typically defined as 16–30 sessions delivered over 4–8 months, has the most robust RCT evidence base within the psychodynamic family. Several major meta-analyses have synthesized this evidence.

Meta-Analytic Evidence

The most comprehensive meta-analysis of STPP was conducted by Abbass, Hancock, Henderson, and Kisely (2006), updated in subsequent publications. This Cochrane-affiliated review included 23 RCTs and found STPP effective for depression, anxiety, somatoform disorders, and personality disorders, with pre-post effect sizes (Cohen's d) ranging from 0.69 to 1.46 for symptom measures. For general symptom distress, the between-group effect size versus waitlist or treatment-as-usual controls was approximately d = 0.97 at termination and d = 1.51 at long-term follow-up — a pattern of continued improvement after treatment ends that is characteristic of psychodynamic approaches.

Driessen and colleagues (2010) conducted a meta-analysis specifically focused on STPP for major depressive disorder, including 23 studies with 1,365 patients. They found a large pre-post effect size of d = 1.34 and a moderate between-group effect size versus control of d = 0.69. Response rates (defined as ≥50% reduction in depression scores) were approximately 50–60%, and remission rates were approximately 30–45%, broadly comparable to CBT and antidepressant medication for mild-to-moderate depression.

Specific Disorder Evidence

Depression: STPP has the strongest evidence base for major depressive disorder. The Helsinki Psychotherapy Study, a major RCT comparing STPP (20 sessions), LTPP (3 years), and solution-focused therapy in depressed adults, found that STPP produced rapid symptom improvement comparable to solution-focused therapy at 7 months, though LTPP showed advantages at 3-year follow-up for patients with personality pathology.

Anxiety disorders: STPP has demonstrated efficacy for generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder, though the evidence base is smaller than for CBT. For panic disorder, Milrod and colleagues (2007) conducted a pivotal RCT comparing panic-focused psychodynamic therapy to applied relaxation training, finding a response rate of 73% for PDT versus 39% for relaxation, a significant difference. This study was influential in establishing PDT as a credible treatment for panic disorder.

Somatoform/somatic symptom disorders: STPP, particularly ISTDP, has shown strong effects for medically unexplained symptoms. Abbass and colleagues have published multiple trials showing significant reductions in somatic symptoms and healthcare utilization, with effect sizes often exceeding d = 1.0.

Personality disorders: STPP has shown moderate effects for personality pathology, though longer-term formats are generally considered more appropriate for entrenched characterological patterns.

Long-term psychodynamic psychotherapy, defined as treatment lasting more than 50 sessions or one year, addresses a different clinical population than STPP: patients with chronic, complex, and treatment-resistant conditions, particularly personality disorders, chronic depression, and complex trauma. The evidence base for LTPP, while smaller and methodologically more challenging, has strengthened considerably.

The Landmark Leichsenring and Rabung (2008, 2011) Meta-Analyses

Falk Leichsenring and Sven Rabung published two influential meta-analyses of LTPP in JAMA (2008) and the Journal of the American Medical Association (updated 2011). The 2008 meta-analysis included 23 studies (11 RCTs and 12 observational studies) and found LTPP superior to shorter forms of psychotherapy for complex mental disorders, with an overall between-group effect size of d = 1.8 for overall outcome. This very large effect size generated significant debate; critics argued that the comparison conditions were often inadequate and that methodological limitations inflated estimates. Nevertheless, even conservative reanalyses supported a moderate-to-large effect (d = 0.5–0.8) for LTPP in complex conditions.

Specific Conditions and Key Studies

Borderline Personality Disorder (BPD): LTPP has its strongest evidence in the treatment of BPD. Two manualized long-term psychodynamic treatments have shown robust efficacy:

• Mentalization-Based Treatment (MBT): Developed by Peter Fonagy and Anthony Bateman, MBT is an 18-month partial hospitalization or intensive outpatient program grounded in attachment theory and the concept of mentalizing — the capacity to understand behavior in terms of mental states. The original Bateman and Fonagy (1999, 2001) RCT showed MBT superior to treatment as usual for BPD across multiple outcomes, including suicidal behavior, self-harm, hospitalization, and depression. At 8-year follow-up, MBT-treated patients maintained gains and continued to improve, while control patients showed limited change. The NNT for preventing suicidal acts was approximately 3–4.
• Transference-Focused Psychotherapy (TFP): Developed by Otto Kernberg and colleagues, TFP is a twice-weekly psychodynamic treatment that directly addresses the distorted internal representations ("object relations") that drive BPD pathology. Clarkin and colleagues (2007) conducted an RCT comparing TFP, Dialectical Behavior Therapy (DBT), and supportive psychotherapy for BPD. TFP showed significant improvements in multiple domains and was the only treatment associated with changes in attachment organization and reflective function, suggesting deeper structural personality change.

Chronic Depression: The Tavistock Adult Depression Study (TADS), published by Fonagy and colleagues in 2015 in World Psychiatry, was a landmark RCT comparing 18 months of weekly psychoanalytic psychotherapy plus treatment as usual versus treatment as usual alone for treatment-resistant depression (patients who had failed at least two adequate antidepressant trials). At the end of treatment, there was no significant difference between groups. However, at 24-month follow-up (6 months post-treatment) and 42-month follow-up, the psychoanalytic therapy group showed significantly higher remission rates: 44% vs. 10% achieved complete remission of major depressive disorder at long-term follow-up. This delayed onset of benefit, sometimes called the "sleeper effect," is a recurring finding in LTPP research and suggests that the therapy initiates processes of change that continue to unfold after formal treatment ends.

Complex Trauma and PTSD: LTPP is increasingly used for complex PTSD (cPTSD), now recognized as a distinct diagnosis in ICD-11. While the evidence base for trauma-focused CBT (TF-CBT) and EMDR is stronger for simple PTSD, patients with complex developmental trauma, dissociative features, and personality comorbidity often require the longer, relationally intensive treatment that LTPP provides. RCT evidence is emerging but limited.

The comparison between psychodynamic therapy and CBT is perhaps the most debated topic in psychotherapy research. A fair reading of the evidence reveals a nuanced picture that defies simplistic conclusions.

Meta-Analytic Findings

The most rigorous meta-analytic comparison was published by Steinert, Munder, Rabung, Hoyer, and Leichsenring (2017) in the American Journal of Psychiatry. This meta-analysis included 23 RCTs directly comparing PDT to CBT across multiple disorders. The overall between-group effect size was d = 0.07 in favor of CBT — a trivially small and statistically non-significant difference. When examined by disorder, the pattern was largely consistent: PDT and CBT produced equivalent outcomes for depression, anxiety disorders, and personality disorders at end of treatment.

However, several important nuances emerged:

• At follow-up: PDT showed a trend toward continued improvement after treatment termination, while CBT gains tended to plateau or show modest decline. This pattern was statistically significant in some analyses, with PDT showing an advantage of approximately d = 0.12–0.20 at follow-up assessments conducted 6–24 months post-treatment.
• For specific disorders: CBT showed modest advantages for specific anxiety disorders (particularly OCD and specific phobias), where disorder-specific CBT protocols (especially exposure-based treatments) have very strong evidence. PDT showed comparable or occasionally superior outcomes for depression, personality disorders, and somatic symptom disorders.
• Allegiance effects: Researcher allegiance — the theoretical orientation of the investigators — significantly predicted outcome differences. Studies conducted by CBT-aligned researchers tended to find CBT advantages; studies by psychodynamically-aligned researchers tended to find PDT advantages. When allegiance was controlled statistically, differences between treatments virtually disappeared.

The Dodo Bird Verdict: Still Flying?

The "Dodo Bird verdict" — the hypothesis that all bona fide psychotherapies produce equivalent outcomes — remains one of the most debated propositions in clinical psychology. The PDT-CBT comparison data generally support this hypothesis for the broad categories of depression and anxiety, though specific exceptions exist. The landmark NIMH Treatment of Depression Collaborative Research Program (TDCRP), published in 1989, compared CBT, interpersonal therapy (IPT, which has psychodynamic roots), imipramine plus clinical management, and pill placebo plus clinical management for major depression. No significant differences emerged between active treatments at termination, though imipramine showed advantages for severe depression. At 18-month follow-up, no treatment group showed clear superiority — a finding that tempered claims of specific treatment superiority.

Differential Treatment Response and Moderators

More clinically useful than asking "which therapy is better?" is asking "which therapy is better for whom?" Several patient characteristics have been identified as potential moderators:

• Psychological mindedness and introspective capacity: Patients with higher psychological mindedness tend to respond better to PDT, while patients who prefer structured, skills-based approaches may do better with CBT.
• Personality pathology: Patients with significant personality disorder comorbidity — particularly Cluster B and Cluster C disorders — may derive greater long-term benefit from PDT, which directly addresses characterological patterns. The Munich Psychotherapy Study (Huber et al., 2012) found that psychoanalytic therapy produced greater personality change than CBT at 3-year follow-up in depressed patients.
• Patient preference: Treatment preference is a significant predictor of outcome. Patients who receive their preferred treatment show better outcomes regardless of modality. A meta-analysis by Swift and Callahan (2009) found that matching patients to preferred treatment reduced dropout by approximately 50%.
• Chronicity and complexity: For chronic, treatment-resistant conditions with multiple comorbidities, LTPP may offer advantages, as evidenced by the TADS study's long-term outcomes for treatment-resistant depression.

Comorbidity is the rule rather than the exception in the patient populations most commonly treated with PDT. Understanding comorbidity patterns is essential for treatment planning and outcome prediction.

Depression and Personality Disorders

Major depressive disorder co-occurs with personality disorders at rates of approximately 40–60% in outpatient psychiatric settings, depending on assessment methods. The most common comorbidities are with Cluster C disorders (avoidant, dependent, and obsessive-compulsive personality disorders), present in approximately 25–35% of depressed outpatients, and borderline personality disorder, present in approximately 10–20%. This comorbidity pattern has major prognostic significance: comorbid personality pathology predicts poorer acute treatment response across all modalities and is associated with a 2–3 fold increase in relapse risk. PDT's direct focus on characterological patterns may explain its superior long-term outcomes in these comorbid populations.

Anxiety and Depression Comorbidity

Approximately 50–60% of patients with an anxiety disorder also meet criteria for major depressive disorder (or vice versa). This comorbidity is associated with greater severity, chronicity, and functional impairment. Psychodynamic formulation, which addresses underlying dimensions (e.g., insecure attachment, unresolved conflict, shame dynamics) rather than disorder-specific symptoms, may be particularly suited to transdiagnostic presentations.

Somatic Symptom Disorders and Medical Comorbidity

Patients with somatic symptom disorders frequently present with comorbid anxiety (~50%), depression (~50–65%), and personality disorders (~30–50%). ISTDP has shown particular promise in this population, with Abbass and colleagues reporting significant reductions in emergency department visits (up to 69% reduction) and healthcare costs following brief PDT interventions.

Substance Use Disorders

Comorbid substance use disorders are present in approximately 20–40% of patients with mood and anxiety disorders. While specific evidence for PDT in substance use disorders is limited, psychodynamic formulations of addiction — emphasizing self-regulation deficits, attachment disruption, and affect intolerance (Khantzian's self-medication hypothesis) — inform integrated treatment approaches.

Identifying who will benefit most — and least — from psychodynamic therapy is a critical clinical question. Research has identified several patient, therapist, and process factors associated with outcome.

Patient Factors Predicting Good Outcome

• Psychological mindedness: The capacity for self-reflection and interest in understanding one's own mental states is consistently associated with better PDT outcomes.
• Quality of object relations (QOR): Patients with a history of at least one stable, meaningful interpersonal relationship tend to fare better in PDT. The QOR scale developed by Azim and colleagues predicts outcome across STPP studies.
• Capacity to form a therapeutic alliance: Early alliance quality (by session 3–5) is one of the strongest predictors of outcome across all psychotherapies, accounting for approximately 5–8% of outcome variance (Horvath et al., 2011 meta-analysis). This effect appears particularly important in PDT.
• Affect tolerance and experiencing capacity: Patients who can access and tolerate emotional experience tend to respond better to expressive psychodynamic techniques.
• Motivation for self-understanding: Intrinsic motivation for insight-oriented change (versus purely symptom-focused goals) predicts better PDT engagement and outcome.

Patient Factors Predicting Poor Outcome

• Severe personality pathology at the low borderline or psychotic level of organization: Patients with significant identity diffusion, primitive defenses (splitting, projective identification), and impaired reality testing may require highly specialized long-term treatments and often show slower, more limited response.
• Active substance dependence: Active, untreated substance use disorders substantially undermine psychotherapy effectiveness across modalities.
• Externalizing defenses and low distress tolerance: Patients who primarily externalize blame and show little subjective distress may have difficulty engaging in the reflective work PDT requires.
• Severe cognitive impairment: PDT requires sufficient cognitive capacity for abstract thought and self-reflection.

Therapist Factors

Therapist effects are substantial in PDT — larger than in manualized CBT. Research consistently shows that therapist competence accounts for 5–10% of outcome variance (some estimates suggest up to 17% in naturalistic settings). In PDT specifically, the therapist's capacity for accurate empathy, interpretive accuracy (interventions that match the patient's level of insight readiness), and ability to manage ruptures in the therapeutic alliance are key competencies. Safran and Muran's research on alliance rupture and repair has demonstrated that successfully navigated ruptures actually predict better long-term outcomes than alliances that remain smooth — a finding with particular relevance for PDT, where transference enactments and relational tensions are expected and therapeutically utilized.

Process Factors

Increasing emotional experiencing over the course of treatment, as measured by the Experiencing Scale, is a robust predictor of good outcome in PDT. Similarly, gains in reflective functioning — the capacity to mentalize one's own and others' mental states — predict sustained improvement. These process variables may represent the specific mechanisms through which PDT produces its effects.

One of the distinctive contributions of psychodynamic thinking to clinical practice is the psychodynamic formulation — an individualized, theory-driven narrative account of the patient's difficulties that goes beyond categorical diagnosis. While DSM-5-TR and ICD-11 provide essential descriptive categories, psychodynamic formulation addresses the why and how of psychopathology: why this patient, with this history, develops these symptoms at this time.

Where Categorical Diagnosis Falls Short

Several clinical scenarios highlight the value of psychodynamic formulation:

• Treatment-resistant depression: When a patient has failed multiple adequate antidepressant trials and disorder-specific psychotherapy, a psychodynamic formulation may reveal that the "depression" is a surface manifestation of unresolved grief, narcissistic vulnerability, or chronic characterological submission — dynamics that require different interventions than a standard CBT depression protocol.
• Repeated relapse: Patients who achieve remission with acute treatment but relapse repeatedly may have underlying personality vulnerabilities (e.g., dependent or masochistic patterns) that maintain vulnerability. PDT's focus on characterological change may address these vulnerability factors.
• Somatization: Medically unexplained symptoms that persist despite thorough medical workup often reflect alexithymia (difficulty identifying and expressing emotions) and defensive somatization. Psychodynamic formulation can identify the unconscious conflicts and affects being expressed through the body.
• Complex comorbidity: When a patient presents with three or four DSM-5-TR diagnoses, a psychodynamic formulation can often identify a unifying dynamic — for example, pervasive shame driving both social anxiety, depressive withdrawal, and binge eating.

The Psychodynamic Diagnostic Manual (PDM-2)

The Psychodynamic Diagnostic Manual, Second Edition (PDM-2), published in 2017, represents an effort to systematize psychodynamic diagnosis. It provides a multi-axis system that includes personality organization (healthy, neurotic, borderline, psychotic levels), personality syndromes/styles, mental functioning profiles, and symptom patterns — organized around the subjective experience of the patient rather than purely behavioral criteria. While the PDM-2 is not as widely adopted as the DSM-5-TR, it provides clinically useful dimensions that complement categorical diagnosis, particularly in treatment planning for psychodynamic therapy.

Despite significant advances, the evidence base for psychodynamic therapy has important limitations and active areas of development.

Key Limitations

• Fewer RCTs than CBT: The psychodynamic research tradition has historically prioritized case studies, process research, and naturalistic outcome studies over RCTs. While the RCT literature has grown substantially, it remains smaller than the CBT evidence base. As of 2023, there are approximately 150+ RCTs of various PDT formats, compared to over 700 RCTs for CBT. This asymmetry partly reflects funding patterns (CBT research has been prioritized by NIMH and other funding bodies) and partly reflects the cultural and methodological preferences of the psychodynamic research community.
• Manualization challenges: PDT is inherently more difficult to manualize than CBT because its technical repertoire is relationally responsive and contextually dependent. This creates challenges for standardization in RCTs and for treatment fidelity measurement.
• Comparison condition problems: Many LTPP studies have used treatment-as-usual as the comparator, which is methodologically weaker than active treatment comparisons. Studies directly comparing LTPP to long-term CBT are virtually nonexistent.
• Publication and allegiance bias: As noted above, researcher allegiance significantly influences reported outcomes, and publication bias affects the PDT literature as it does all psychotherapy research.

Emerging Research Directions

Mechanism research: The field is moving from "Does PDT work?" to "How does PDT work?" Process-outcome research is identifying specific mechanisms of change, including increased reflective functioning, improved emotion regulation capacity, defense maturation, and changes in internal working models of attachment. The development of reliable measures like the Reflective Functioning Scale and the Defense Mechanism Rating Scales has facilitated this work.

Precision psychotherapy: Emerging research on treatment selection aims to identify patient characteristics that predict differential response to PDT versus CBT. The Personalized Advantage Index (PAI) developed by DeRubeis and colleagues represents a promising approach, using baseline patient variables to generate individualized predictions of which treatment will produce the best outcome for a given patient.

Intensive short-term dynamic psychotherapy (ISTDP): ISTDP has emerged as a particularly active area of research, with growing RCT evidence for treatment-resistant depression, somatic symptom disorders, and personality disorders. Its brevity (often 8–20 sessions) and manualized structure make it more amenable to controlled research.

Digital and technology-assisted PDT: The COVID-19 pandemic accelerated the adoption of videoconference-delivered PDT, with emerging evidence suggesting equivalent outcomes for teletherapy PDT compared to in-person delivery, at least for STPP. Research on internet-based psychodynamic interventions is in early stages.

Neurobiological outcome predictors: Baseline neuroimaging features — such as sgACC activity, amygdala reactivity, and resting-state functional connectivity patterns — are being investigated as predictors of differential treatment response. Early evidence suggests that patients with high baseline amygdala reactivity may respond preferentially to psychotherapy (including PDT) over medication.

Several major clinical guidelines now include PDT among recommended treatments for specific conditions:

• NICE (UK National Institute for Health and Care Excellence): Recommends STPP as a second-line treatment for mild-to-moderate depression (after CBT and behavioral activation) and recognizes MBT as a recommended treatment for BPD. LTPP is recognized for chronic depression and complex presentations.
• APA (American Psychiatric Association): The APA Practice Guidelines for major depressive disorder list psychodynamic therapy as an evidence-based psychotherapy option, though CBT and IPT receive stronger endorsements based on the volume of RCT evidence.
• German S3 Guidelines: Germany's national guidelines for depression and anxiety disorders give psychodynamic therapy equal standing with CBT, reflecting the strong psychodynamic research tradition in German-speaking countries.
• The Cochrane Collaboration: Has published systematic reviews supporting STPP for depression, common mental disorders, and somatic symptom disorders.

In clinical practice, PDT is often most appropriately indicated when: (1) the patient has not responded adequately to first-line evidence-based treatments; (2) the clinical picture is dominated by personality pathology, chronic interpersonal difficulties, or characterological patterns; (3) the patient is psychologically minded and motivated for self-understanding; (4) the presenting problems are chronic and multifaceted rather than acute and circumscribed; or (5) the patient prefers an insight-oriented, relationally-focused approach. Treatment selection should always be a shared decision informed by the evidence base, clinical formulation, and patient preference.

Psychodynamic therapy in its modern forms is a clinically effective, neurobiologically plausible, and increasingly well-evidenced treatment modality. The key findings from the contemporary evidence base can be summarized as follows:

• STPP produces effect sizes in the moderate-to-large range (d = 0.69–1.46) across multiple disorder categories, with response rates of 50–60% for depression and anxiety disorders.
• LTPP shows efficacy for complex, chronic, and treatment-resistant conditions — particularly BPD (MBT, TFP) and treatment-resistant depression (TADS) — with distinctive patterns of continued improvement after treatment termination.
• Head-to-head comparisons with CBT show no clinically meaningful differences for most conditions (d = 0.07 overall), with PDT showing a modest advantage at follow-up and CBT showing advantages for specific anxiety disorders with exposure-based protocols.
• Neurobiological changes following PDT include normalization of prefrontal-limbic circuitry, reduction in amygdala hyperreactivity, changes in subgenual cingulate activation, and modulation of HPA axis function.
• The evidence base, while growing, remains smaller than that for CBT, and methodological improvements — particularly more active-comparator RCTs and mechanism-focused research — are needed.

The clinical bottom line is that psychodynamic therapy deserves a place in the evidence-based treatment armamentarium, particularly for patients with complex, chronic, and relationally-based difficulties. The most scientifically honest position is not that one therapy is universally superior, but that different patients respond to different treatments — and that our field's most urgent task is developing better methods for matching individual patients to their optimal treatment.